Mineralys Therapeutics operates in the biotechnology sector, concentrating on the development of therapeutic innovations. The company recently drew attention amid a broader surge in biotech valuations. According to the article, Mineralys secured $9.5 million in new capital from Findell Capital Management, giving it additional liquidity to advance its research initiatives. While the report does not outline specific drug candidates or clinical programs, the fresh funding underscores investor confidence in the firm’s scientific direction. The financing also signals the company’s intent to accelerate upcoming milestones and strengthen its operational footing. No revenue figures, user metrics, or detailed pipeline information were disclosed in the article.

Total raised

$168M

Funding rounds

3

Latest round

Equity

Latest activity

Nov 2025